Skip to main content
This section contains press releases and other materials from third parties (including paid content). The Globe and Mail has not reviewed this content. Please see disclaimer.

Wall Street Analysts Are Bullish on Top Healthcare Picks

Tipranks - Tipranks - Tue Nov 25, 2025

There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on CSPC Pharmaceutical Group (CHJTF – Research Report), Wuxi Biologics (Cayman) (WXIBF – Research Report) and Ocular Therapeutix (OCUL – Research Report) with bullish sentiments.

TipRanks Black Friday Sale

CSPC Pharmaceutical Group (CHJTF)

In a report issued on November 20, Jialin Zhang from Nomura maintained a Buy rating on CSPC Pharmaceutical Group, with a price target of HK$9.11. The company’s shares closed last Wednesday at $0.95, close to its 52-week high of $0.96.

Zhang has an average return of 15.6% when recommending CSPC Pharmaceutical Group. ;'>

According to TipRanks.com, Zhang is ranked #741 out of 10113 analysts.

The word on The Street in general, suggests a Moderate Buy analyst consensus rating for CSPC Pharmaceutical Group with a $1.43 average price target, a 50.3% upside from current levels. In a report issued on November 20, Citi also maintained a Buy rating on the stock with a HK$12.10 price target.

See Insiders’ Hot Stocks on TipRanks >>

Wuxi Biologics (Cayman) (WXIBF)

Morgan Stanley analyst Laurence Tam maintained a Buy rating on Wuxi Biologics (Cayman) on November 20 and set a price target of HK$35.00. The company’s shares closed last Monday at $4.04.

According to TipRanks.com, Tam is ranked #8104 out of 10113 analysts.

Currently, the analyst consensus on Wuxi Biologics (Cayman) is a Strong Buy with an average price target of $5.33.

Ocular Therapeutix (OCUL)

William Blair analyst Lachlan Hanbury Brown maintained a Buy rating on Ocular Therapeutix yesterday. The company’s shares closed last Monday at $12.10.

According to TipRanks.com, Brown is a 4-star analyst with an average return of 19.0% and a 60.0% success rate. Brown covers the Healthcare sector, focusing on stocks such as Apellis Pharmaceuticals, Tarsus Pharmaceuticals, and Kalaris Therapeutics. ;'>

Currently, the analyst consensus on Ocular Therapeutix is a Strong Buy with an average price target of $22.70.

Read More on CHJTF:

Disclaimer & DisclosureReport an Issue

This article contains syndicated content. We have not reviewed, approved, or endorsed the content, and may receive compensation for placement of the content on this site. For more information please view the Barchart Disclosure Policy here.

All market data (will open in new tab) is provided by Barchart Solutions. Copyright © 2026.

Information is provided 'as is' and solely for informational purposes, not for trading purposes or advice. For exchange delays and terms of use, please read disclaimer (will open in new tab).